Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation

Leukemia

Volumn 14, Issue 10, 2000, Pages 1766-1776

  Tse, K F ^a   Mukherjee, G ^a   Small, D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CBL; FLT3; JAK2; Leukemia; STAT5; Transformation

Indexed keywords

FLT3 LIGAND; HELIX LOOP HELIX PROTEIN; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3; MEMBRANE RECEPTOR; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BLAST CELL CRISIS; CANCER MORTALITY; CELL INFILTRATION; CELL LINEAGE; CELL PROLIFERATION; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HISTOPATHOLOGY; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

EID: 0033820091     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401905     Document Type: Article

References (77)

1. Hematopoietic growth factors and the regulation of differentiative decisions
2. Cytokine receptors and signal transduction
3. Cellular hematopoiesis in the twentieth century
4. Growth factor receptor tyrosine kinases
5. The protein kinase family conserved features and deduced phylogeny of the catalytic domains
6. Hematopoietic receptors of class III receptor-type tyrosine kinases
7. STK-1, the human homolog of Flk-2/FLT-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells
8. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase
9. Expression of the Flt3 receptor and its ligand on hematopoietic cells
10. Flt3(high) and Flt3(low) CD34+ progenitor cells isolated from human bone marrow are functionally distinct
11. Multi-level effects of Flt3 ligand on human hematopoiesis: Expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors
12. Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro
13. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors
14. Flk2/Flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors
15. Targeted disruption of the Flk2/Flt3 gene leads to deficiencies in primitive hematopoietic progenitors
16. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs
17. Effect of Flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells
18. C-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
19. Receptor protein-tyrosine kinases and their signal transduction pathways
20. Dimerization of cell surface receptors in signal transduction
21. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells
22. Substrate specificities and identification of a putative binding site for P13K in the carboxy tail of the murine Flt3 receptor tyrosine kinase
23. Analysis of the mitogenic pathway of the FLT3 receptor and characterization in its C terminal region of a specific binding site for the P13' kinase
24. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates
25. Flt3 signaling involves tyroslphosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells
26. P85 Subunit of P13 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells
27. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
28. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias
29. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
30. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface face of normal and malignant hematopoietic cells
31. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells
32. Effects of Flt3 ligand on human leukemia cells 1. Proliferative response of myeloid leukemia cells
33. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: Regulation of Bcl-2 and Bax
34. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines
35. Flt3-ligand production by human bone marrow stromal cells
36. Expression of Flt3-ligand by the endothelial cell
37. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: Heterogeneity in response and synergy with other hematopoietic growth factors
38. C-fms expression in acute leukemias with complex phenotypes
39. M-CSF and M-CSF receptor gene expression in acute myelomonocytic leukemias
40. The roles of stem cell self-renewal and autocrine growth factor production in the biology of myeloid leukemia
41. Interleukin-6-type cytokines in myeloproliferative disease
42. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia
43. Internal tandem duplication of the Flt3 gene found in acute myeloid leukemia
44. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia
45. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children
46. Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
47. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRB oncoprotein
48. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia
49. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
50. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms
51. The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic meylomonocytic leukemia is a transforming protein that self-associates and activates PDGFBR kinase-dependent signaling pathways
52. The novel activation of ABL by fusion to an ets-related gene, TEL
53. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia
54. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
55. Switching signals on or off by receptor dimerization
56. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis
57. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
58. The SH3 domain-binding T cell tyrosyl phosphoprotein p120. Demonstration of its identity with the c-cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase
59. The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigen receptor
60. V-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas
61. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins
62. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase
63. Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand
64. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines
65. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6
66. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation
67. Requirement for Y706 of the murine (or Y708 of the human) CSF-1 receptor for STAT1 activation in response to CSF-1
68. Formation of STAT5-containing DNA binding complexes in response to colony-stimulating factor-1 and platelet-derived growth factor
69. Stat1 associates with c-kit and is activated in response to stem cell factor
70. Stem cell factor activates STAT-5 DNA binding in IL-3-derived bone marrow mast cells
71. C-cbl is transiently tyrosine-phosphorylated, ubiquininated, and membrane-targeted following CSF-1 stimulation of macrophages
72. The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells
73. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells
74. The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner
75. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK like c-ABL, p190 BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway
76. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia
77. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor